Related by context. All words. (Click for frequent words.) 77 detectable HCV RNA 74 undetectable virus HCV 74 undetectable viral load 74 sustained virologic response 73 SVR# 72 virologic failure 71 ribavirin RBV 71 rapid virologic response 71 HCV RNA 71 sustained virological response 70 undetectable hepatitis C 70 log# reduction 70 virologic response 69 HBeAg seroconversion 69 undetectable HBV DNA 69 complete cytogenetic 69 ACR# response 69 peginterferon 69 Pegasys plus Copegus 68 copies mL 68 IU mL 68 CCyR 68 CIMZIA TM 68 IU ml 68 mg kg dose 68 sUA 68 plasma HCV RNA 67 achieved sustained virologic 67 mg QD 67 peginterferon alfa 2a 67 PEG IFN 67 evaluable 67 peg interferon 67 HIV RNA 67 CR nPR 67 evaluable subjects 67 #mg BID [001] 67 evaluable patients 66 ribavirin therapy 66 HBV DNA levels 66 timepoint 66 complete cytogenetic response 66 cEVR 66 RECIST criteria 66 serum HBV DNA 66 null responders 66 RGT arm 66 virological response 66 Sustained virologic response 66 peg IFN 66 biochemical relapse 66 Crohn Disease Activity 66 mg/m2 dose 66 plasma uric acid 66 serum phosphorus 65 HCV RESPOND 2 65 mcg kg 65 LEXIVA r 65 mcg BID 65 Sustained Virological Response 65 achieved PASI 65 copies ml 65 serum HCV RNA 65 PASI scores 65 PegIFN RBV 65 achieved ACR# 65 pegylated interferon peg IFN 65 pegylated interferon alpha 65 virologic response EVR 65 HbA1c levels 65 Peg IFN 65 achieved sustained virological 65 remission CR 65 mg TID 65 HBeAg positive patients 64 plus ribavirin 64 mg BID 64 Virologic 64 endoscopic remission 64 viral kinetics 64 achieved CCyR 64 Solid Tumors criteria 64 relapsed MM 64 pegylated interferon 64 ACR# responses 64 #mg dose [002] 64 undetectable viral 64 rapid virological response 64 MCyR 64 CRp 64 HBV DNA 64 certolizumab 64 ACR# [002] 64 FOLFOX6 64 virologic 64 RECIST Response Evaluation Criteria 64 CR CRu 64 mRCC 64 EGFR TKI 63 chlorambucil 63 #mg QD [001] 63 mg/m2/day 63 dosing cohorts 63 #mg QD [002] 63 glycated hemoglobin levels 63 metastatic CRC 63 Median PFS 63 APTIVUS r 63 bortezomib refractory 63 log# IU mL 63 adefovir 63 progression TTP 63 Index CDAI 63 serum phosphorous 63 REYATAZ r 63 HCV SPRINT 63 PSA nadir 63 CDAI score 63 mcg albinterferon alfa 2b 63 PREZISTA r 63 lamivudine refractory patients 63 telaprevir dosed 63 administered subcutaneously 63 atazanavir ritonavir 63 seroconversion 63 8mg/kg 63 primary efficacy endpoint 63 prior chemotherapy regimens 63 virologic suppression 62 peginterferon alfa 2b 62 Aptivus ® 62 recurrent glioblastoma multiforme 62 lamivudine monotherapy 62 Rapid Virological Response 62 dose cohort 62 secondary endpoint 62 receiving VICTRELIS 62 pegylated interferon alfa 62 virological failure 62 induction regimen 62 adefovir treated 62 Hb A1C 62 #mg/m# [002] 62 severe neutropenia 62 q#h 62 adalimumab 62 Pharmacokinetic parameters 62 HBeAg 62 highly emetogenic 62 genotypic resistance 62 RNA copies mL 62 log# 62 BARACLUDE ® 62 mg qd 62 HCV genotype 62 clinically meaningful improvement 62 R# #mg BID 62 cytogenetic response 62 placebo dexamethasone 62 ug kg 62 tipranavir ritonavir 62 null responder HCV 62 #mg/day [002] 62 prospectively defined 61 piperacillin tazobactam 61 ACTEMRA TM 61 lopinavir r 61 naïve HCV 61 decitabine 61 mg ustekinumab 61 plus methotrexate 61 plus dexamethasone 61 median PFS 61 QTcF 61 gout flares 61 aspartate aminotransferase AST 61 serum testosterone 61 partial remissions 61 q#d 61 DAS# CRP 61 CIMZIA TM certolizumab pegol 61 serum urate 61 lymphocytosis 61 mg RDEA# 61 IV NSCLC 61 imatinib therapy 61 alfa 2a 61 VELCADE melphalan 61 peginterferon alfa 2a #KD 61 refractory NSCLC 61 FOLFOX4 61 virological suppression 61 LPV r 61 clodronate 61 #mg BID [002] 61 serum phosphate 61 HBeAg positive 61 interferon ribavirin 61 ng dL 61 antiretroviral naive 61 oral allopurinol 61 seropositive patients 61 Viral load 61 CDAI 61 Elitek 61 % CI #.#-#.# [003] 61 log# copies mL 61 3mg/kg 61 Free Survival PFS 61 Partial Response 61 dose escalation phase 61 macroalbuminuria 61 octreotide LAR 61 anagrelide 61 CIMZIA ™ 61 CMV disease 61 mcg dose 61 pCR 61 HBeAg negative patients 61 ABC/3TC 61 abacavir lamivudine 61 μg dose 61 sunitinib 61 tipranavir r 61 hepatitis C genotype 61 neurologic progression 61 patients evaluable 60 IFN α 60 viral load 60 DAS# remission 60 5-FU/LV 60 rFVIIa 60 annualized relapse 60 posttransplant 60 Response Evaluation Criteria 60 valopicitabine 60 #mg BID [003] 60 recurrent GBM 60 baminercept 60 COPEGUS 60 posaconazole 60 BENICAR 60 posttreatment 60 HbA1c 60 Primary endpoints 60 complete Early Virological 60 PROMACTA 60 Sprycel dasatinib 60 Engerix B 60 CrCl 60 COMBIVIR 60 EXJADE 60 mucosal healing 60 achieve sustained virologic 60 adjunctive placebo 60 postdose 60 Median survival 60 lumiliximab 60 Solid Tumors 60 spontaneous bowel movements 60 IPSS 60 oral rivaroxaban 60 MVax R 60 TMC# r 60 nonresponders 60 MADRS score 60 lopinavir r arm 60 secondary efficacy endpoints 60 pegylated interferon alfa 2a 60 Solid Tumors RECIST 60 binary restenosis 60 mL/min/#.# m 2 60 adalimumab Humira 60 ACR Pedi 60 hemoglobin A1c HbA1c 60 experienced virologic failure 60 fasting plasma glucose FPG 60 ALT flares 60 nitazoxanide 60 treatment naïve genotype 60 prespecified 60 XIENCE V PROMUS Stent 60 HbA 1c 60 dose cohorts 60 mg/m2 IV 60 oxycodone CR 60 PSADT 60 -#.# log# 60 BENICAR HCT 60 detemir 60 mg m² 60 VFEND 60 nab paclitaxel 60 mcg QD 60 timepoints 60 NATRECOR R 60 baseline HbA1c 60 LANTUS R 60 OGTT 60 hemoglobin A1c levels 60 ALT normalization 60 mg q8h 60 desvenlafaxine succinate 60 Cmax 60 Copegus ribavirin 60 postintervention 60 oral ridaforolimus 60 ritonavir boosted 60 virologic breakthrough 60 PegIFN 60 viremia 60 recurrent genital herpes 60 virus HCV protease inhibitor 60 Peginterferon Alfa 2a 60 viral suppression 60 glufosfamide 60 alanine aminotransferase ALT 60 Lupuzor ™ 60 Psoriasis Area 60 tipranavir 60 locoregional disease 60 mcg Albuferon 60 insulin detemir 60 Median progression 60 peginterferon alfa 60 4mg/kg 60 GOUT 59 microgram kg 59 rimonabant #mg 59 corticosteroid dose 59 saline placebo 59 oral FTY# 59 response CCyR 59 EDSS scores 59 GSK# [001] 59 pg mL 59 DAPT 59 lispro 59 #.#mg/dL 59 ipsilateral stroke 59 dosing cohort 59 aminotransferase elevations greater 59 chronic HCV infection 59 HCV genotype 1 59 urate lowering therapy 59 postprocedure 59 mg dose 59 metastatic renal cell carcinoma 59 μg kg 59 elevated ALT 59 mCRC patients 59 #mg/day [001] 59 Aflibercept 59 achieved undetectable HCV 59 hours postdose 59 Pegylated Interferon 59 docetaxel chemotherapy 59 postmenopausal osteoporotic women 59 pegylated interferon alfa 2b 59 secondary efficacy endpoint 59 treatment naive genotype 59 μmol L 59 CD4 + cell 59 Insulin PH# 59 NIHSS 59 chemoradiation therapy 59 HCV Genotype 59 riociguat 59 ertapenem 59 sinus rhythm 59 ancrod 59 noninferior 59 alanine aminotransferase 59 HAQ DI 59 ULORIC 59 chronic HCV genotype 59 dacarbazine 59 NovoLog ® Mix 59 RECIST 59 NLX P# 59 MARINOL R 59 mg/m2 59 neoadjuvant chemotherapy 59 Pegasys peginterferon alfa 2a 59 infliximab 59 low dose cytarabine 59 tamoxifen therapy 59 morphometric vertebral fractures 59 metastatic malignant melanoma 59 primary endpoint 59 g dL 59 Doxil ® 59 free survival PFS 59 Index CDAI score 59 mg kg intravenously 59 R0 resection 59 Telbivudine 59 elevated transaminases 59 peginterferon alpha 2a 59 Pemetrexed 59 low dose Iluvien 59 specific antigen PSA 59 creatinine clearance 59 microalbuminuria 59 tocilizumab 59 randomized #:#:# 59 underwent surgical resection 59 HBeAg negative 59 prospectively stratified 59 Lantus ® 59 glycosylated hemoglobin HbA1c 59 systemic ALCL 59 oral methylnaltrexone 59 fasting plasma glucose 59 cART 59 biochemical recurrence 59 entecavir 59 reduce serum phosphate 59 angiographic outcomes 59 weekly intravenous infusions 59 sipuleucel T 59 mg subcutaneously 59 antibody titer 59 hypokalemia 59 Kaplan Meier estimate 59 mesalamine granules 59 q8h 59 GnRH agonist 58 refractory CLL 58 noninferiority 58 ISENTRESS 58 HCV infected 58 interferon alfa 58 comparator arm 58 CLARITY study 58 ibandronate 58 mitoxantrone 58 OADs 58 underwent resection 58 radioiodine therapy 58 liver histology 58 dosed intravenously 58 divalproex sodium 58 Fludara 58 bosentan 58 nicardipine 58 tenofovir emtricitabine 58 efficacy endpoint 58 lanthanum carbonate 58 hypogonadal men 58 galiximab 58 antiretroviral naïve 58 goserelin 58 mitoxantrone plus 58 alteplase 58 Dasatinib 58 cytarabine daunorubicin 58 NPH insulin 58 infliximab therapy 58 rizatriptan 58 platelet reactivity 58 TDF FTC 58 recurrent atrial fibrillation 58 degarelix 58 Traficet EN 58 ATACAND 58 dapagliflozin plus 58 tolvaptan 58 relapsing MS 58 CTAP# Capsules 58 sitagliptin 58 Pegasys ® 58 PEG Interferon alfa 58 underwent liver transplantation 58 seroprotection 58 lactate dehydrogenase LDH 58 HbA1C 58 anthracycline taxane 58 mg d 58 mapatumumab 58 alemtuzumab treated 58 PREZISTA ritonavir 58 plus prednisone 58 Raptiva r 58 intermittent dosing 58 mcg mL 58 Partial Responses 58 MULTAQ 58 nodular partial response 58 amoxicillin clavulanate 58 glycated hemoglobin HbA1c 58 calculated creatinine clearance 58 #mg/m# [001] 58 Secondary endpoints 58 stage IIIb IV 58 urinary N telopeptide 58 HSCT 58 FOLPI 58 pegylated interferon alpha 2a 58 iPTH 58 dasatinib 58 titrated 58 subcutaneously administered 58 PEG interferon 58 postoperatively 58 Target Lesion Revascularization TLR 58 PEGINTRON TM 58 inhibitor RG# 58 FIRMAGON 58 heavily pretreated 58 active comparator 58 virologic responses 58 plus MTX 58 acute STEMI 58 serum urate levels 58 rilonacept 58 abnormal p# biomarker 58 A1C levels 58 VICTRELIS 58 pyrazinamide 58 thyroglobulin 58 randomized #:# 58 ENDEAVOR II 58 AZOR 58 Kaplan Meier analysis 58 perioperatively 58 hypophosphatemia 58 dosing intervals 58 interferon beta therapy 58 mg eq 58 serum phosphate levels 58 transaminases 58 phase IIb study 58 dosage regimens 58 definite stent thrombosis 58 STRIDE PD 58 incontinence episodes 58 oral vancomycin 58 glycated hemoglobin 58 antiangiogenic therapy 58 p = NS 58 Follicular Lymphoma 58 ARB telmisartan 58 dexamethasone Decadron 58 Omacetaxine 58 CHOP chemotherapy 58 RESIST studies 58 HBsAg 58 rindopepimut 58 viral loads 58 concomitant antibiotics 58 CK # plasma concentrations 58 resectable 58 cinacalcet 58 inadequate glycemic 58 #mg/dl 58 paricalcitol 57 subcutaneous enoxaparin 57 Scale EDSS 57 pegfilgrastim 57 ribavirin USP 57 acute gout flares 57 DAS# [002] 57 iloprost 57 statistical significance p 57 vandetanib 57 ug dose 57 virologically 57 Complete Response CR 57 #mg q8h 57 REYATAZ r arm 57 tumor recurrence 57 intact parathyroid hormone 57 enoximone 57 Flu Cy 57 placebo intravenously 57 dalteparin 57 glycosylated hemoglobin 57 baseline LDH 57 PRADAXA #mg 57 STELARA 57 Prograf ® 57 ADAS cog 57 oral prednisone 57 placebo p = 57 mL/min/#.# m2 57 SCr 57 #.#ng/ml 57 NATRECOR ® 57 adjuvant tamoxifen 57 mcg doses 57 Tipranavir 57 #mg/kg [002] 57 A1c levels 57 pmol L 57 argatroban 57 mg/# hr 57 oblimersen 57 stage IIIB 57 insulin degludec 57 HbA 1c levels 57 TMC# [002] 57 oral antidiabetic medication 57 clevidipine 57 Bezielle 57 darbepoetin alfa 57 azacitidine 57 complete remissions 57 serum potassium 57 Phase 2a trial 57 FOLFIRI 57 β blockers 57 refractory AML 57 bisphosphonate therapy 57 zolmitriptan 57 chemoradiotherapy 57 phase IIb trial 57 chronic HCV 57 neoadjuvant therapy 57 elotuzumab 57 alpha 2a 57 hematological parameters 57 relapsed multiple myeloma 57 dose titration 57 prior relapsers 57 CSBM 57 telaprevir dosing 57 warfarin therapy 57 EGFR expressing mCRC 57 periprocedural 57 HAM D# scores 57 CAELYX 57 boceprevir 57 moderately emetogenic 57 invasive aspergillosis 57 postvaccination 57 lipid lowering therapy 57 Capesaris 57 aminotransferase levels 57 INFERGEN 57 ascending dose 57 unresectable stage 57 mg kg hr 57 RRMS patients 57 Hycamtin ® 57 HCV viral 57 VIRAMUNE 57 colorectal liver metastases 57 preintervention 57 intravitreal injection 57 Jevtana 57 EDSS score 57 % Confidence Interval 57 Rapid Virologic Response 57 curative resection 57 tapentadol ER 57 GAMMAGARD 57 IV bisphosphonates 57 TAXUS Stent 57 splenectomized patients 57 mg orally 57 taxane chemotherapy 57 colesevelam HCl 57 serum aminotransferase levels 57 odanacatib 57 PREZISTA r arm 57 MabCampath 57 REYATAZ R 57 FluCAM 57 recurrent VTE 57 postoperative chemotherapy 57 Gleevec imatinib 57 tumor shrinkage 57 Secondary endpoints include 57 dose cytarabine 57 PREZISTA rtv 57 confirmed CCyR 57 lumbar spine BMD 57 irbesartan 57 Golimumab 57 virologically suppressed 57 ONGLYZA ™ 57 carvedilol 57 paraprotein 57 mutated KRAS 57 canakinumab 57 Lupuzor TM 57 paroxysmal AF 57 EDARBI 57 intravenous diuretics 57 MAGE A3 ASCI 57 Decitabine 57 Durezol 57 tolterodine ER 57 #mg ATC 57 blood phenylalanine Phe 57 CLL SLL 57 achieved statistical significance 57 teriflunomide 57 HUMIRA achieved PASI 57 interferon therapy 57 SCIg 57 ritonavir boosted atazanavir 57 plus gemcitabine 57 pharmacokinetic PK profile 57 APTIVUS 57 overt nephropathy 57 #mg doses [002] 57 MoxDuo TM IR 57 Myelodysplastic Syndrome MDS 57 HAART 57 primary endpoints 57 FOLFOX 57 etanercept 57 serum uric acid 57 standard chemotherapy regimen 57 INC# 57 monotherapy 57 aspartate aminotransferase 57 nutlin 3a 56 T#I [002] 56 MIRCERA 56 epoetin alfa 56 anthracycline containing 56 ischemic cardiomyopathy 56 ALVESCO 56 cells uL 56 Expanded Disability Status 56 ritonavir boosted lopinavir 56 composite endpoint 56 IRLS score 56 HPV-#/# 56 receiving prophylactic anticoagulation 56 certolizumab pegol 56 Platelet counts 56 mg simvastatin 56 Naive Patients 56 plasma concentrations 56 NMIBC 56 Sustained Virologic Response 56 nilotinib 56 gemcitabine carboplatin 56 Ishak fibrosis score 56 Nesiritide 56 adenoma recurrence 56 CsA 56 mg tid 56 gastrointestinal stromal tumors 56 cytogenetic responses 56 TURBT 56 TMC# [001] 56 activated partial thromboplastin 56 blastic phase 56 5-fluorouracil/leucovorin 56 BoNTA 56 drug eluting stent implantation 56 ximelagatran 56 KRAS status 56 EDEMA3 trial 56 nadolol 56 TORISEL 56 YERVOY 56 fosamprenavir 56 operable pancreatic cancer 56 idarubicin 56 elagolix 56 metastatic RCC 56 Rate ORR 56 non inferiority 56 maximal doses 56 mCi kg 56 anemia hemoglobin 56 serum clusterin levels 56 Trastuzumab 56 mealtime insulin 56 Peginterferon 56 chronic angina 56 romiplostim 56 efavirenz EFV 56 rt PA 56 ara C 56 #mg dose [001] 56 ALND 56 trastuzumab Herceptin ® 56 surrogate endpoint 56 pomalidomide 56 achieving PASI 56 ACZ# 56 Sustained virological response 56 omega interferon 56 EMPHASIS HF trial 56 oral anticoagulation 56 receptor tyrosine kinase inhibitor 56 azathioprine 56 Lamictal XR 56 cells mcL 56 EDEMA4 trial 56 ZOLINZA 56 Q#IR 56 Montgomery Asberg Depression 56 cardiovascular calcification 56 flutamide 56 Topotecan 56 hypomagnesemia 56 coronary revascularization 56 imatinib 56 BEACOPP 56 rolofylline 56 Amrubicin 56 mg q#h 56 infusional 5-FU/LV 56 hour bronchodilation 56 Retreatment 56 mmol l 56 clinically meaningful 56 pretreatment baseline 56 follicular lymphomas 56 CK MB 56 DMARD 56 FROVA 56 TYKERB 56 oral antidiabetes 56 LVEF 56 Non inferiority 56 hyperphenylalaninemia HPA due 56 Dose escalation 56 inotropic 56 Cethromycin 56 bezafibrate 56 metastatic HRPC 56 ZD# [001] 56 median CD4 56 relapsed MCL 56 baseline FEV 56 LHRH analogues 56 HDRS 56 FOLFOX4 alone 56 undetectable viral loads 56 infliximab monotherapy 56 primary efficacy endpoints 56 IRESSA 56 1mg dose 56 clinically meaningful improvements 56 dexmedetomidine 56 transaminase levels 56 QTc prolongation 56 estimated glomerular filtration 56 PEGylated Fab fragment 56 F FDG PET 56 LIALDA 56 primary patency 56 ALT elevation 56 placebo 56 Secondary endpoints included 56 LEXIVA 56 PegIntron 56 aminotransferase ALT 56 eosinophilic asthma 56 weekly subcutaneous injections 56 octreotide 56 mEq L 56 CAMMS# 56 CANCIDAS 56 peginterferon ribavirin 56 edifoligide 56 aminotransferases 56 zonisamide SR 56 docetaxel prednisone 56 nucleoside naive 56 baseline A1C 56 carboplatin paclitaxel 56 HBeAg + 56 IOP lowering 56 lymphocyte count 56 limiting toxicity 56 receiving INTRON 56 microalbumin test 56 imetelstat 56 NNRTI resistance 56 doripenem 56 topotecan 56 relapsers 56 calcineurin inhibitor 56 mg dL 56 Contrave# 56 RSD# oral 56 rFSH 56 cytoreduction 56 remission induction 56 Pred Forte 56 VGPR 56 5 Fluorouracil 56 Severity Index PASI 56 mIU mL 56 protease inhibitor PI 56 fulvestrant 56 fluvastatin 56 CCR5 tropic HIV 56 IELT 56 Xelox 56 metastatic GIST 56 olmesartan 56 -#.# mg dL [002] 56 Virologic failure 56 gout flare 56 haematologic 56 mL sec 56 IV bolus 56 dosing interval 56 systolic dysfunction 56 interferon alfa 2b 56 plus prednisone prednisolone 56 chemo radiotherapy 56 alefacept 56 Victoza R 56 Unified Parkinson Disease 56 beta blocker therapy 56 histologically confirmed 56 Capacity FVC 56 MADIT II 56 NNT = 56 alkylating agent 56 metastatic renal cell 56 rALLy trial 56 dasatinib Sprycel ® 56 serum phosphorus levels 56 eltrombopag 56 superficial bladder cancer 56 leukemia AML 56 PEGINTRON 56 sUA levels 56 febrile neutropenia 56 LMWH 56 cells μL 56 KRAS wild 56 IFN alfa 56 systemic corticosteroids 56 de novo kidney transplant 56 Natalizumab 56 cytotoxic therapy 56 liposome injection 56 lamivudine 56 prospective randomized placebo 56 systemically administered 56 methotrexate therapy 56 lopinavir 55 Peg riba 55 CD4 cell 55 tamsulosin 55 BRIM3 55 placebo PBO 55 non splenectomized 55 pegylated alpha interferon 55 Hb levels 55 PROCHYMAL 55 cGy 55 nadroparin 55 OPT CHF 55 APPRAISE 55 Acute Ischemic Stroke 55 bFGF 55 statistically significant p = 55 Actilon 55 PEG INTRON 55 fibrinolysis 55 CMV infection 55 candesartan cilexetil 55 APTIVUS R 55 seroconverted 55 preoperatively 55 interquartile range 55 INCB# [003] 55 hemoglobin concentrations 55 Viread Emtriva 55 paliperidone ER 55 blood Phe 55 SPRYCEL ® 55 AVELOX 55 pegIFN 55 moderate renal impairment 55 apremilast 55 estramustine 55 relapsing remitting MS RRMS 55 randomized multicenter trial 55 COPAXONE R 55 radezolid 55 AZT zidovudine Retrovir 55 SSRI SNRI 55 unblinded 55 KOMBIGLYZE XR 55 T2DM 55 HGS ETR1 55 RLAI 55 APOPTONE 55 valacyclovir 55 genotype 1b 55 FOLFIRI alone 55 Castration Resistant Prostate Cancer 55 XELOX